Extracellular cold-inducible RNA-binding protein (eCIRP) is a recently-discovered damageassociated molecular pattern. Understanding the precise mechanism by which it exacerbates inflammation in sepsis is essential. Here we identified that eCIRP is a new biologically active endogenous ligand of triggering receptor expressed on myeloid cells-1 (TREM-1), fueling inflammation in sepsis and ischemia-reperfusion. Surface plasmon resonance revealed a strong binding affinity between eCIRP and TREM-1, and FRET assay confirmed eCIRP's interaction with TREM-1 in macrophages. TREM-1 inhibition, either by its siRNA or a decoy peptide LP17, dramatically reduced eCIRP-induced inflammation. We developed a novel 7-aa peptide derived from human eCIRP, M3, which blocked the interaction of TREM-1 and eCIRP. M3 suppressed inflammation induced by eCIRP or agonist TREM-1 Ab crosslinking in murine macrophages or human peripheral blood monocytes. M3 also inhibited eCIRP-induced systemic inflammation and tissue injury. Treatment with M3 further protected mice from sepsis and intestinal ischemiareperfusion, improved acute lung injury, and increased survival. Thus, we have discovered a novel TREM-1 ligand and developed a new peptide M3 to block eCIRP-TREM-1 interaction and improve the outcome of sepsis and sterile inflammation.
Introduction
Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) play leading roles in fueling inflammation in both infectious and sterile systemic insults, such as those that occur during sepsis or ischemia/reperfusion (I/R) injury 1, 2, 3 . Coldinducible RNA-binding protein (CIRP) is a 18-kDa RNA chaperone protein 4 . In addition to the passive release due to necrotic cell death, CIRP can be released extracellularly during sepsis, hemorrhage or I/R injury, translocating from the nucleus to cytoplasmic stress granules before being released to the extracellular space 5 . Extracellular CIRP (eCIRP) acts as a DAMP, causing severe inflammation and organ injury 5, 6 . Elevated plasma levels of eCIRP have been correlated with a poor prognosis in patients with sepsis 5, 7 . Being a new DAMP, a complete understating of eCIRP's pathobiology in inflammatory diseases is required to develop novel therapeutics.
Similar to other DAMPs, eCIRP recognizes Toll-like receptor 4 (TLR4) 5, 8 expressed in macrophages, lymphocytes, and neutrophils to increase cytokine production 5 , T cell polarization 9 , and neutrophil activation 10 . Healthy mice injected with recombinant murine (rm) CIRP developed acute lung injury (ALI) via activation of macrophages, neutrophils, and endothelial cells, and displayed increased vascular permeability in the lungs 11, 12 . Conversely, CIRP -/mice were protected from sepsis and ALI 5, 6 . Consistent with these findings, treatment of septic animals with a neutralizing antibody against eCIRP attenuated organ injury and prolonged survival 5, 6 . Collectively these findings indicate that eCIRP is a major contributing factor in the pathogenesis of sepsis; targeting eCIRP is a valid strategy to mitigate sepsis severity.
Triggering receptor expressed on myeloid cells-1 (TREM-1) is an innate immune receptor expressed primarily on neutrophils and macrophages 13 . TREM-1 activation triggers inflammation independently 14 , as well as by synergizing with the TLR4 pathways 14, 15 . TREM-1 activation leads to DNAX-activating protein of 12 kDa (DAP12) phosphorylation 13, 15 which promotes activation of the tyrosine kinase Syk 16 , resulting in the production of cytokines and chemokines 15, 16 . The ligands for TREM-1 remain elusive, with only high mobility group box 1 (HMGB1) 17 , extracellular actin 18 , and peptidoglycan recognition protein 1 (PGLYRP1) 19 identified thus far. The nature of the TREM-1 ligand(s) and mechanisms of TREM-1 signaling
are not yet thoroughly explored. Identification of a new natural endogenous TREM-1 ligand will not only help improve our understanding of the pathophysiology of inflammatory diseases, but also discover new therapeutic avenues against those diseases.
Both eCIRP and TREM-1 are upregulated in sepsis to serve as mediators of inflammation 5, 20 , but their interaction has not been studied. In sepsis, both eCIRP and TREM-1 reside extracellularly 5, 20 , giving rise to the hypothesis that eCIRP could be a novel endogenous ligand of TREM-1. In this study, we have discovered that eCIRP is a new biologically active endogenous TREM-1 ligand and their interaction fuels inflammation. We have also developed a unique human eCIRP-derived ligand-dependent 7 amino acid peptide (RGFFRGG) to serve as an antagonist of TREM-1, named M3, and implemented M3 as a therapeutic in pre-clinical models of sepsis and I/R injury. Our findings provide an effective therapeutic target against sepsis and sterile inflammatory diseases.
Results

Identification of eCIRP as a new TREM-1 ligand to promote inflammation
To study the direct interaction between eCIRP and TREM-1, we performed a surface plasmon resonance (SPR) assay, which demonstrated a strong binding between rmCIRP and rmTREM-1 with a KD of 11.7 × 10 -8 M (Fig 1A) . An immunofluorescence study was performed to confirm the co-localization of eCIRP and TREM-1 in macrophages after rmCIRP stimulation. It clearly demonstrated the co-localization of rmCIRP and TREM1, as indicated by the merged (yellow) image (Fig 1B) . Conversely, rmCIRP did not co-localize with a negative control, the macrophage pan marker CD11b (Fig 1B) . We next performed FRET analysis to quantitatively determine rmCIRP's association with TREM-1. FRET analysis revealed a clear association between rmCIRP and TREM-1 with an increase in FRET units of nearly 7-fold compared to rmCIRP's interaction with negative control CD11b (Fig 1C) . These findings implicate that eCIRP is a novel TREM-1 ligand. We then studied the activation of downstream molecules DAP12 and Syk in macrophages treated with rmCIRP and found robust increase in the phosphorylation of DAP12 and Syk at 10 min after rmCIRP stimulation (Fig 1D-F; Supplemental Fig 1A-E) . We next confirmed the functional role of TREM-1 in eCIRPmediated inflammation. We found that the siRNA-treated macrophages showed significant inhibition of TNF-α production following rmCIRP stimulation ( Fig 1G) . Similarly, the treatment of macrophages with LP17, an inhibitor of TREM-1 21 , dose-dependently inhibited rmCIRPinduced TNF-α production in RAW264.7 cells ( Fig 1H) . Conversely, the scramble peptide for LP17 did not show any inhibition of TNF-α production ( Fig 1H) . Collectively, these data clearly show that eCIRP specifically binds to TREM-1 in macrophages and induces TNF-α production.
TREM-1 expression in macrophages is increased in sepsis 15 . To explore the role of eCIRP on this increase, RAW264.7 cells and murine primary peritoneal macrophages were stimulated with rmCIRP. TREM-1 mRNA levels were increased 2.5-fold in rmCIRP-treated RAW264.7 cells as compared to PBS control ( Supplemental Fig 2A) . The protein levels of TREM-1 expression on the cell surface of both RAW264.7 cells and primary murine peritoneal macrophages treated with rmCIRP were significantly increased by 4.3 and 1.6-fold, respectively, compared to PBS control (Supplemental Fig 2B, C) .
An eCIRP-derived antagonist M3 inhibits the eCIRP-TREM-1 interaction production (Fig 2E) . Similarly, M3 treatment was also able to significantly inhibit the production TNF-α in rmCIRP-stimulated primary human PBMC obtained from healthy volunteers where the highest inhibition of 76% in TNF-α production occurred at 10 g/ml of M3 treatment ( Fig 2F) .
Collectively, we have discovered a novel small peptide M3 which blocks the eCIRP-TREM-1 interaction and inhibits eCIRP-mediated inflammation.
M3 inhibits eCIRP or LPS-induced inflammation in mice
Having established M3 as an antagonist of eCIRP and TREM-1 binding, we sought to evaluate its efficacy in reducing systemic inflammation in vivo. Administration of rmCIRP in healthy mice dramatically increased serum levels of IL-6 and IL-1, and M3 treatment decreased these levels by 50% and 24%, respectively (Fig 3A, B) . Lung mRNA levels of TNF-, IL-1, and KC were significantly increased by rmCIRP injection into mice, while M3 treatment reduced their expression by 65%, 74%, and 45%, respectively (Fig 3C-E) . We further proved that pharmacologic inhibitor of TREM-1 using LP17 attenuated rmCIRP-induced systemic inflammation and lung injury in mice (Fig 4) . Treatment of mice with LP17 dramatically reduced the levels of AST, ALT, and LDH in the serum of rmCIRP-injected mice by 77%, 82%, and 54%, respectively, compared to vehicle-treated rmCIRP-injected mice (Fig 4A-C) . The levels of IL-6, IL-1, and IFN- in the serum were significantly decreased by 72%, 66%, and 86%, respectively in LP17-treated mice (Fig 4D-F) . LP17 treatment significantly attenuated TNF-, IL-1, and IL-6 mRNA by 80%, 59%, and 93%, respectively, (Fig 4G-I) and proteins by 24%, 63%, and 30% respectively, in the lungs (Fig 4J-L) . Similarly, treatment with LP17 significantly reduced the expression of chemokines MIP-2 and KC and adhesion molecules ICAM-1 and VCAM-1 mRNA in the lungs (Supplemental Fig 4A-D) . Histological images of lung tissue showed increased levels of alveolar congestion, exudate, interstitial and alveolar cellular infiltrates, intra-alveolar capillary hemorrhages, and damage of epithelial architecture, in rmCIRP-injected mice compared to sham mice ( Fig 4M) . LP17 treatment dramatically improved these histological injury parameters in rmCIRP-injected mice ( Fig 4M) . These histological changes were reflected in a significant decrease in lung tissue injury score in LP17-treated mice by 48% ( Fig 4N) . LPS is known to stimulate eCIRP release by the macrophages 5 . Using an endotoxemia model, we demonstrated that M3 treatment was able to reduce serum levels of IL-6 and TNF- by 31% and 80%, respectively (Fig 3F, G) . Administration of M3 during endotoxemia increased the 7-day survival from 70% to 100% ( Fig 3H) . Therefore, TREM-1 is involved in eCIRP-mediated inflammation and tissue injury, and blockade of the eCIRP-TREM-1 interaction attenuates inflammation.
M3 protects mice from polymicrobial sepsis
We next evaluated the efficacy of M3 in a more clinically relevant model of sepsis utilizing CLP in mice. CLP caused robust increases in organ injury markers AST and LDH in the serum, while the M3 treated mice showed significant decrease in their levels by 17% and 53%, respectively (Fig 5A, B) . Similarly, the serum IL-6 and TNF- were elevated by CLP, however M3 treatment significantly reduced these levels by 84% and 27%, respectively (Fig 5C, D) . Expression of the pro-inflammatory cytokines IL-6, TNF-, and chemokine KC mRNA in lung tissues were increased in CLP-induced sepsis, and were dramatically reduced with M3 treatment (Fig 5E-G) .
Histological images of lung tissue in CLP mice displayed significant damage, with increased levels of alveolar congestion, proteinaceous debris, interstitial and alveolar neutrophil infiltration, intra-alveolar capillary hemorrhages, and damage of epithelial architecture ( Fig 5H) .
M3 treatment dramatically improved these histological injury parameters in septic mice ( Fig   5H) . These histological changes were reflected in a significant decrease in lung tissue injury score in M3-treated mice compared to vehicle mice ( Fig 5I) . To determine if M3 was able to improve survival in sepsis, mice were subjected to CLP and randomized to treatment with M3 or vehicle. We found that M3 treatment increased the survival rate from 45% to 80% at day 10 after CLP ( Fig 5J) . In summary, the released eCIRP in sepsis binds to TREM-1 and potentiates the expression of pro-inflammatory cytokines. Administration of M3, by inhibiting the eCIRP-TREM-1 interaction, exhibits excellent therapeutic potential against murine polymicrobial sepsis.
M3 protects mice against sterile inflammation caused by intestinal I/R
As eCIRP is known to be involved in systemic and pulmonary inflammation in ischemia reperfusion injury 6 , we evaluated the impact of M3 treatment in a murine model of intestinal I/R injury. Intestinal I/R increased serum levels of AST by 7.9-fold, ALT 3.8-fold, LDH 57.8-fold, and lactate 3.5-fold. M3 drastically improved these organ injury markers with decreases of 50%, 66%, 417%, and 47%, respectively (Fig 6A-D) . Intestinal I/R increased the serum levels of IL-6 and TNF- by 12.4 and 7.5-fold, retrospectively, while M3 treatment significantly reduced these elevations by 41% and 77%, respectively (Fig 6E, F) . Lung mRNA levels of IL-6, IL-1, and MIP-2 were significantly increased by I/R. These increases were reduced by 82%, 96%, and 89% in M3 treated I/R mice (Supplemental Fig 5A-C) . Protein levels of IL-6, IL-1, and MIP-2 were increased in intestinal I/R treated mice, and M3 treatment resulted in significant reduction of 40%, 56%, and 45%, respectively (Fig 6G-I) . Histological images of lung tissue showed increased levels of alveolar congestion, exudate, interstitial and alveolar cellular infiltrates, intraalveolar capillary hemorrhages, and damage of epithelial architecture, in mice who underwent intestinal I/R compared to sham mice ( Fig 6J) . M3 treatment dramatically improved these histological injury parameters in intestinal I/R mice ( Fig 6J) . These histological changes were reflected in a significant decrease in lung tissue injury score in M3-treated compared to vehicletreated mice by 65% ( Fig 6K) . M3 also doubled 24-h survival rate after I-I/R, from 40% to 80%.
( Fig 6L) . These results indicate that M3 is also efficacious in sterile inflammation.
Discussion
Extracellular CIRP has been recently identified as a DAMP that is released during sepsis, shock, and ischemia/reperfusion injury 5, 6 . However, its molecular mechanism to induce inflammation still remains enigmatic. Despite identification of the TREM-1 receptor nearly two decades ago 13 , its ligand(s) are not well elucidated. Our study fills a significant previous knowledge gap by establishing a novel link between eCIRP and TREM-1 demonstrated by several in vitro studies using murine and primary human macrophages and in vivo models clinically relevant to both sterile and infectious inflammatory diseases. We summarized the overall findings in We have, for the first time, identified eCIRP as an endogenous ligand for TREM-1. In other word, TREM-1 is a new receptor for eCIRP. Previously, TLR4 was the only identified receptor for eCIRP 5, 6 . We hypothesized that, like most DAMPs, eCIRP has several receptors for signal transduction. HMBG1, for example, is known to potentiate signals through TLR2, TLR4, receptor for advanced glycation end product (RAGE), TREM-1, and CD163 23, 24, 25 . Using SPR we found a strong KD of 11.7 x 10 -8 M of binding between eCIRP and TREM-1, which is comparable to the dissociation constant of the previously identified receptor for eCIRP, TLR4 5 .
Of the known ligands for TREM-1: PGLYRP1 19 , extracellular actin 18 , and HMGB1 17 , SPR has been used between TREM-1 and PGLYRP1 and HMGB1. Surprisingly, the KD between eCIRP and TREM-1 (11.7 × 10 -8 M) was more than two orders lower than the KD between HMGB1 and TREM-1 (35.4 x 10 -6 M) 17 , indicating higher binding affinity of eCIRP to TREM-1 than between HMGB1 and TREM-1. In addition to SPR, several additional approaches were taken to confirm the physical interaction of eCIRP and TREM-1, including confocal microscopy and FRET analysis.
After demonstrating eCIRP's binding to TREM-1, the focus was shifted to determining if eCIRP's binding to TREM-1 resulted in fueling inflammation and causing tissue injury. This was a crucial step, as we previously demonstrated that although SPR displays binding of eCIRP to TLR2 and RAGE, there are no functional outcomes of this association 5 . Inhibition of TREM-1 by siRNA showed some, but not complete, reduction in the production of pro-inflammatory cytokine by the macrophages treated with eCIRP. This could be due to off target effects of TREM-1 siRNA on other TREMs, although this remains speculative. TREM family contains TREM-1, TREM-2, and, in mice, TREM-3 26 . Although TREM-1 contains an immunoreceptor tyrosine-based activation motif (ITAM), additional TREM family members contain an immunoreceptor tyrosine-based inhibitory motif (ITIM), and thus they could play anti-inflammatory role 27, 28 . In addition, macrophages deficient in TREM-2 are hyperresponsive to TLR ligands 29 . We therefore used another approach to inhibit TREM-1 by LP17 which abrogated eCIRP-induced inflammation and ALI, confirming the notion that the eCIRP-TREM-1 interaction is functionally dynamic. LP17 is a 17 amino acid peptide whose sequence is taken from TREM-1; it is thought to function as a decoy receptor 21 . We attempted to determine the interaction between LP17 and eCIRP using SPR and demonstrated a KD of 48 x 10 -6 M between these two molecules (data not shown). This could be artificially elevated due to conditions present in vivo that we cannot reproduce artificially, such as involvement of other biological cofactors, temperature, and molecular stability. The TREM-1 antagonists function primarily as decoy receptors and to prevent receptor dimerization 21, 30 . Additionally, Sigalov et al has developed a ligand-independent inhibitor of TREM-1 31, 32 . Although use of these peptides in animal models of inflammatory diseases has resulted in decreased inflammation and improved survival, it is not clear which ligand of TREM-1 these decoy peptides neutralize, rendering their use somewhat less specific. Here, we have developed a ligand dependent TREM-1 inhibitor, a novel short peptide M3. As demonstrated with FRET analysis and functionally in vitro and in vivo, M3 is able to prevent eCIRP's interaction with TREM-1 thereby impeding eCIRP's proinflammatory role.
Both the specificity to the eCIRP and TREM-1 interaction and the small size of M3 may prove advantageous in future therapeutic applications of M3. M3 has a molecular weight of 795.9 Daltons. Most peptides in clinical use are injected subcutaneously. Peptides under 1 kDa can be absorbed directly into the systemic circulation via blood capillaries, whereas larger peptides are absorbed initially through the lymphatic system or in a combination of both blood and lymphatic absorption 33, 34 . Additionally, because patient compliance is increased with noninvasive administration, small peptides have an advantage over larger peptides. In the current study, we demonstrated M3 had an excellent inhibitory role in mitigating inflammation not only in macrophage cells, but also in bacterial sepsis and sterile inflammation. Prior to usage of M3 in large animal models or human clinical trials, further studies on the stability, half-life, and safety would be required. However, at the doses used here, M3 did not demonstrate immunogenicity or tissue injury as demonstrated by cytokine levels, organ injury markers, or histologic analysis.
In addition to eCIRP's interaction with TREM-1, we also found that the expression of TREM-1 in macrophages was increased following treatment with eCIRP. Several studies have established the connection between TLR4 and TREM-1 in immune cells 14, 35, 36 . The cellular consequences of TREM-1 activation following treatment with anti-TREM-1 Ab were examined in terms of global gene expression and compared with cells receiving LPS and also cells receiving a combined treatment of anti-TREM-1 plus LPS 14 . The results indicated that besides having the crosstalk with TLR4, TREM-1 signaling independently promoted the expression of some unique genes 14 , implying the direct impact of TREM-1 pathway in inflammation. As previously discussed, like other DAMPs, eCIRP has been shown to recognize TLR4 5 . TLR4 activation leads to upregulation of TREM-1 expression which is MyD88-dependent and involves transcription factors NF-κB, PU.1 and AP1 37 . Additionally, simultaneous activation of TREM-1 and TLR4 leads to synergistic production of pro-inflammatory mediators through common signaling pathway activation including PI3K, ERK1/2, IRAK1 and NF-κB activation 13, 14, 15, 16 .
Thus, the upregulation of TREM-1 expression in macrophages after treatment with eCIRP could be promoted through both TLR4 and TREM-1-dependent pathways. The connection between TLR4 and TREM-1 has been shown in neutrophils: following LPS stimulation of neutrophils, TREM-1 was found to be co-localized with TLR4 36 . Genetic deletion of TREM-1 downregulates the expression of several genes implicated in the TLR4 pathway including MyD88, CD14 and IκBα 35 . Our data demonstrating the eCIRP-induced expression of pro-inflammatory cytokines by the macrophages also supports the synergistic effects of TREM-1 and TLR4.
However, to demonstrate the independent pro-inflammatory role of the TREM-1 in eCIRPmediated inflammation, we activated TREM-1 using agonist antibody crosslinking 13, 14 . TREM-1 activation resulted in increased levels of TNF-α; however, TNF-α production was diminished in cells treated with M3. M3 interfered with the crosslinking effect demonstrating a TLR4 independent interaction between eCIRP and TREM-1.
In summary, we have discovered that eCIRP is a new ligand of TREM-1 in macrophages.
We have developed a small peptide, M3, which successfully reduces systemic inflammation and improves survival in murine models of infectious and sterile inflammation. 
Methods
Experimental animals
C57BL/6 male mice were purchased from Charles River Laboratories (Wilmington, MA). Age 
Animal model of polymicrobial sepsis
Mice were anesthetized with inhaled isoflurane and placed in supine position. Cecal ligation and puncture (CLP) was preformed through a midline laparotomy 39, 40 . Briefly, the abdomen was shaved and disinfected. A 2-cm incision was created, the cecum was exposed, and ligated with a Vehicle group received an equivalent volume of PBS. After 90 min, mice were sacrificed, and serum was collected for analysis. To study survival rates, mice were treated with 15 mg/kg BW LPS (Escherichia coli serotype O55:B5; Sigma-Aldrich) with or without 10 mg/kg BW M3 and were evaluated twice daily for 7 days.
Animal model of intestinal ischemia/reperfusion
Mice were anesthetized with inhaled isoflurane and the abdomen was shaved and disinfected. 
In vivo administration of rmCIRP, LP17 and M3
rmCIRP was produced in our lab as previously described 5 glutamine. Cells were maintained in a humidified incubator with 5% CO 2 at 37 °C.
Determination of organ injury markers
Serum levels of lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate were determined using specific colorimetric enzymatic assays (Pointe Scientific, Canton, MI) according to the manufacturer's instructions.
Enzyme-linked immunosorbent assay (ELISA)
Supernatant or serum was analyzed by ELISA kits specific for interleukin (IL)-6, tumor necrosis factor-α (TNF-), interferon-γ (IFN-), (BD Biosciences, San Jose, CA), IL-1 (Invitrogen, Carlsbad, CA), and macrophage inflammatory protein-2 (MIP-2) (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. The lung tissue was crushed in liquid nitrogen, and equal weights of powdered tissues (~50 mg) were dissolved in 500 µl of lysis buffer (10 mM Hepes, pH 7.4, 5 mM MgCl2, 1 mM DTT, 1% Triton X-100, and 2 mM each of EDTA and EGTA), and subjected to sonication on ice. Protein concentration was determined by the BioRad protein assay reagent (Hercules, CA). Equal amounts of proteins (250-500 µg) were loaded into respective ELISA wells for the assessment of TNF-, IL-6, MIP-2, and IL-1β.
Lung pathohistology
Lung tissues were fixed in 10% formalin prior to being embedded in paraffin. Tissues were cut into 5 μm sections and stained with hematoxylin and eosin (H&E). Slides were evaluated under light microscopy to evaluate the degree of lung injury. Scoring was done using a system created by the American Thoracic Society 42 . Scores ranged from zero to one and were based on the presence of proteinaceous debris in the airspaces, the degree of septal thickening, and neutrophil infiltration in the alveolar and interstitial spaces. The average score per field was calculated at 400× magnification.
Assessment of TREM-1 expression in macrophages by flow cytometry
To detect TREM-1 expression on the surface of macrophages, a total of 1 × 10 6 RAW264.7 or primary peritoneal macrophages were washed with FACS buffer containing PBS with 2% FBS and stained with APC anti-mouse TREM-1 Ab (clone: 174021, R&D systems). Unstained cells were used as a negative control to establish the flow cytometer voltage setting. Acquisition was performed on 10,000 events using a BD LSR Fortessa flow cytometer (BD Biosciences, San Jose, CA) and data were analyzed with FlowJo software (Tree Star, Ashland, OR).
Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted from tissue using Trizol reagent (Invitrogen, Carlsbad, CA). cDNA was synthesized using MLV reverse transcriptase (Applied Biosystems, Foster City, CA). PCR reactions were carried out in 20 μl of a final volume of 0.08 μM of each forward and reverse primer ( Supplemental Table 1) , cDNA, water, and SYBR Green PCR master mix (Applied Biosystems). Amplification and analysis was conducted in a Step One Plus real-time PCR machine (Applied Biosystems). Mouse β-actin mRNA was used as an internal control for amplification and relative gene expression levels were calculated using the CT method.
Relative expression of mRNA was expressed as fold change in comparison with sham tissues. 
Immunoprecipitation and Western blotting
Stimulation of cytokine production by TREM-1 engagement
To activate RAW264.7 cells through TREM-1, 96-well flat bottom plates were pre-coated with 20 μg/ml of an agonist anti-TREM-1 mAb (clone 174031; R&D Systems) overnight at 37C, similar to previously described protocols 13, 15 . The wells were washed with sterile PBS and 5 × 10 4 cells/well were plated. Cells treated with M3 or scramble M3-Sc1 were premixed with the peptide for 30 min before adding to the well. TNF- production was measured in the culture supernatants after an additional 24 h of incubation.
Surface plasmon resonance
To examine the direct interaction between eCIRP and TREM-1, surface plasmon resonance 
FRET analyses
FRET analysis was performed as described previously 43 . RAW264.7 cells were treated with rmCIRP at 4C for 10 min with or without M3 or scramble peptide, fixed in a nonpermeabilized fashion, and stained using the antibodies and protocol listed under Immunofluorscence methods.
Cell associated fluorescence was measured on Biotek Synergy Neo2 (Biotek, VT) at 566 nm upon excitation at 488 nm (E1), at 681 nm after excitation at 630 nm (E2), and at 681 nm after excitation at 488 nm (E3). The transfer of fluorescence was calculated as FRET units. FRET unit
Statistical analysis
Data represented in the figures are expressed as mean ± SE. ANOVA was used for one-way comparison among multiple groups and the significance was determined by the Student- 
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